Advertisement
AMGN vs PFE
Which Stock Would AI Choose? Amgen (AMGN) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- AMGN trades near $385 with a market capitalization of approximately $208 billion, reflecting stronger profitability margins compared to PFE.
- PFE offers a dividend yield around 6.2 percent, significantly higher than AMGN’s approximate 2.6 percent yield.
- Recent market activity shows AMGN experiencing volatility after a late-August peak near $447, influenced by sector-wide trial developments.
- PFE maintains a larger revenue base but lower net margins, with shares trading in the $27–$29 range amid ongoing patent transitions.
- AMGN reported robust second-quarter results and received FDA approval updates for key therapies in recent weeks.
- Both stocks operate in the healthcare sector with exposure to innovative medicines, though AMGN focuses more narrowly on biotechnology while PFE has broader pharmaceutical operations.
Introduction
Amgen (AMGN) and Pfizer (PFE) represent two established players in the healthcare sector, each with distinct business models and market positions. This comparison examines their recent performance, financial characteristics, and relative positioning to assist traders and investors evaluating biotechnology and pharmaceutical exposure. The analysis draws on observable market data and company developments from recent weeks, providing a factual basis for understanding how these stocks have behaved amid broader sector dynamics.
AMGN Overview and Recent Performance
Amgen Inc. develops and commercializes innovative therapies primarily in oncology, inflammation, and cardiovascular areas. In recent market activity, shares reached a peak near $447 in late August before declining, including a notable single-session drop of approximately 10 percent in early September linked to competitor trial results affecting sentiment on similar pipeline assets. The stock has since stabilized around $385, reflecting a pullback from highs but remaining elevated year-to-date. Recent positive catalysts include strong second-quarter earnings with revenue growth exceeding 9 percent year-over-year and an FDA update reducing monitoring requirements for Imdelltra, a tarlatamab therapy. These factors have supported underlying business momentum despite short-term volatility.
PFE Overview and Recent Performance
Pfizer Inc. maintains a diversified portfolio spanning primary care, oncology, and vaccines, with a larger overall revenue base. Shares have traded within a relatively narrow band between approximately $27 and $29 in recent weeks, showing modest fluctuations amid ongoing adjustments to post-pandemic product contributions and patent expirations. Year-to-date performance has been positive but more measured compared to peers in the biotechnology space. The company continues to advance new product launches and combination therapies, with recent emphasis on oncology candidates. Dividend distributions remain a consistent feature, supported by the company’s scale, though overall margins trail those of more specialized biotechnology firms.
Trending AI Robots
Tickeron operates a platform featuring hundreds of AI trading bots that execute strategies across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions are featured in the curated Trending AI Robots section. Available bots span a range of performance metrics, with historical win rates often falling between 55 percent and 75 percent depending on timeframe and strategy, alongside varied drawdown profiles and trade frequencies. Each bot employs distinct approaches, including momentum, mean-reversion, and multi-timeframe models, applied to different asset sets. Review the full selection on the Trending AI Robots page to identify configurations matching specific objectives.
Head-to-Head Comparison
Amgen operates with a concentrated biotechnology focus and higher operating margins near 23 percent, while Pfizer’s broader pharmaceutical model generates substantially higher absolute revenue but lower net margins around 7 percent. Growth drivers for AMGN center on pipeline execution and recent regulatory updates, whereas PFE emphasizes portfolio diversification and new product offsets to patent losses. Recent momentum favors AMGN in terms of earnings beats, though it carries greater price volatility. Risk factors include clinical trial outcomes for both, with PFE additionally navigating larger-scale revenue transitions. Sector exposure overlaps in healthcare innovation, yet AMGN exhibits lower beta historically, while market sentiment has shown sharper reactions to AMGN news flow in recent periods.
Tickeron AI Verdict
Based on observable factors including earnings consistency, margin strength, and recent regulatory progress, Tickeron’s AI models currently assign a modestly higher probabilistic preference to AMGN for trend stability and catalyst alignment within the observed timeframe. PFE registers competitive positioning on yield and scale but trails on relative profitability metrics. This assessment reflects pattern recognition across available data rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and PFE is a Hold.
AMGN | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 8 | 100 | |
SMR RATING 1..100 | 14 | 83 | |
PRICE GROWTH RATING 1..100 | 20 | 32 | |
P/E GROWTH RATING 1..100 | 27 | 5 | |
SEASONALITY SCORE 1..100 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (8) in the Biotechnology industry is in the same range as PFE (20) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
AMGN's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's SMR Rating (14) in the Biotechnology industry is significantly better than the same rating for PFE (83) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's Price Growth Rating (20) in the Biotechnology industry is in the same range as PFE (32) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (5) in the Pharmaceuticals Major industry is in the same range as AMGN (27) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | PFE | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 67% | 3 days ago 39% |
| Stochastic ODDS (%) | 3 days ago 55% | 3 days ago 52% |
| Momentum ODDS (%) | 3 days ago 61% | 3 days ago 59% |
| MACD ODDS (%) | 3 days ago 69% | 3 days ago 58% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 60% | 3 days ago 49% |
| Advances ODDS (%) | 13 days ago 61% | 5 days ago 54% |
| Declines ODDS (%) | 6 days ago 47% | 7 days ago 56% |
| BollingerBands ODDS (%) | 4 days ago 66% | 3 days ago 50% |
| Aroon ODDS (%) | 3 days ago 52% | 3 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 5 FA rating(s) are green while PFE’s FA Score has 3 green FA rating(s).
- AMGN’s FA Score: 5 green, 0 red.
- PFE’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 8 TA indicator(s) are bullish while PFE’s TA Score has 2 bullish TA indicator(s).
- AMGN’s TA Score: 8 bullish, 2 bearish.
- PFE’s TA Score: 2 bullish, 6 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.94% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.73% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.53%. For the same industry, the average monthly price growth was -5.20%, and the average quarterly price growth was +5.33%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-2.53% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +1.65% | ||
| BMY - PFE | 57% Loosely correlated | -0.77% | ||
| AMGN - PFE | 52% Loosely correlated | +1.82% | ||
| BIIB - PFE | 48% Loosely correlated | +3.33% | ||
| NVS - PFE | 47% Loosely correlated | +0.45% | ||
| SNY - PFE | 47% Loosely correlated | -0.40% | ||
More | ||||